Journal Article

Evaluation of the <i>in vitro</i> activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the <i>Bacteroides fragilis</i> group

David R. Snydman, Nilda V. Jacobus and Laura A. McDermott

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 55, issue 6, pages 1024-1028
Published in print June 2005 | ISSN: 0305-7453
Published online April 2005 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dki107
Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

Objectives: To compare the in vitro activity of NVP-LMB415 (formerly referred to as NVP-PDF 713) with that of other agents with anti-anaerobe activity against clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.

Methods: The MICs for 405 B. fragilis group and 102 Gram-positive anaerobic isolates were determined using NCCLS-recommended procedures. The activity of NVP-LMB415 was compared with that of cefoxitin, clindamycin, imipenem, garenoxacin, linezolid, moxifloxacin and tigecycline. Vancomycin was included in the evaluation of the Gram-positive organisms.

Results: NVP-LMB415 showed excellent in vitro activity against all the species of the B. fragilis group isolates (MIC range ≤ 0.03–0.5 mg/L and MIC90 0.5 mg/L). NVP-LMB415 was active against B. fragilis group strains resistant to β-lactams, quinolones or clindamycin, and the MICs were much lower than those of newer agents such as linezolid, tigecycline and garenoxacin. The MICs of NVP-LMB415 ( ≥ 4 mg/L) for Clostridium species were higher than the MICs for other anaerobes.

Conclusions: Given the frequency of isolation of anaerobic bacteria and their increasing resistance to all classes of antibiotics, NVP-LMB415 is an ideal agent for potential use against mixed infections caused by resistant anaerobic pathogens such as of B. fragilis and Gram-positive aerobic strains such as methicillin-resistant staphylococci, streptococci and enterococci.

Keywords: novel peptide deformylase inhibitor; peptide deformylase inhibitor (PDF); bacterial metalloproteases; anaerobic pathogens

Journal Article.  1614 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.